School of Medicine


Showing 41-50 of 106 Results

  • Chaitanya K. Joshi

    Chaitanya K. Joshi

    Postdoctoral Scholar, Biochemistry

    BioI'm a Stanford Data Science Fellow and postdoc with Rhiju Das at the Department of Biochemistry. I build lab-in-the-loop AI for RNA biology, pairing deep learning with wet-lab experiments at scale.

    I did my PhD in Computer Science at the University of Cambridge with Pietro Liò, on geometric deep learning for molecular design. I built gRNAde, the first 3D generative model for RNA, and validated it in the wet lab as a visiting researcher in Phil Holliger's group at the MRC LMB. I've also interned at Prescient Design (Genentech) and FAIR Chemistry (Meta AI), and my work has been recognized by the Qualcomm Innovation Fellowship and the A*STAR National Science Scholarship.

  • Israel Juarez Contreras

    Israel Juarez Contreras

    Postdoctoral Scholar, Biochemistry

    Current Research and Scholarly InterestsSterols are the most abundant lipid in the plasma membrane. Their structure is deeply conserved, built though a long iterative evolutionary process whose end products are the topology of the fused steroid ring system and the structure of the aliphatic tail extending from it. Together these let the molecule pack tightly against the acyl chains of neighboring lipids, which is how sterols reinforce the membrane and set its fluidity. This same interaction produces a second effect. Sterols associate preferentially with saturated lipids, particularly sphingolipids, and that preference sorts the bilayer into ordered domains, often called lipid rafts, which concentrate certain proteins and exclude others.

    The Bloch hypothesis holds that the sterol biosynthetic pathway was progressively selected for membrane function, with each step yielding a molecule better suited to the bilayer than the one before it. Fluidity has historically been taken as the property under selection, but it is not the only one. Rebuilding ergosterol biosynthesis stepwise in living yeast showed that domain formation imposes its own demands, and that the two properties are not optimized by the same modifications. The pathway alternates between them, arriving at structures that regulate fluidity and organization together rather than either alone. A further design principle follows from this. The pairing between a sterol and the acyl chain length of its partner sphingolipid is highly specific. Replacing the native pathway in yeast with cholesterol biosynthesis abolished the domains ergosterol supports, since ergosterol pairs with the very long acyl chains of fungal sphingolipids while cholesterol pairs with the shorter chains of mammalian membranes.

    These principles, observed in fungi, carry direct consequences for mammals, where cholesterol occupies two distinct pools. One is structural, held in complex with sphingolipids and other lipids. The other is a residual fraction, free or accessible that carries out essential roles in signaling and homeostasis. Accessible cholesterol is defined operationally, by what a probe can bind, but what it corresponds to physiochemically remains open. My central goal is to define accessible cholesterol through a more rigorous biophysical lens and connect that definition to the machinery in cells.

  • Sharada Kalanidhi

    Sharada Kalanidhi

    Director of Data Science, Biochemistry - Genome Center

    Current Role at StanfordCurrent Research: Mathematical Medicine

    The essential challenge is not merely to solve a problem, but to discover the mathematical framework in which the problem can be understood — a perspective associated with the mathematician Alexander Grothendieck.

    We spent decades using sophisticated mathematics to understand financial markets. What happens when we bring that same mathematical direction—and deeper ideas from pure mathematics—to understanding human biology?

    This question captures the intellectual motivation behind Sharada's current work: developing the foundations of Mathematical Medicine, a proposed new discipline that draws on pure mathematics to address fundamental challenges in individualized diagnosis, personalized therapeutics, cancer treatments, and healthy longevity.

    The work begins with a central challenge in contemporary medicine. Advances in genomics, proteomics, metabolomics, and computational biology have generated unprecedented volumes of biomedical data. Yet translating these measurements into meaningful insights for individual patients remains difficult, particularly for those with rare, complex, or previously unexplained conditions.

    Conventional statistical and machine learning approaches have transformed biomedical research, but their reliance on population-level patterns can limit their usefulness when an individual patient's biology differs substantially from that of available reference cohorts. Clinically meaningful differences may be treated as statistical noise or outliers rather than investigated as potential clues to underlying disease mechanisms.

    After more than a decade of research and collaboration with biochemists at SGTC, Sharada became increasingly interested in whether the mathematical foundations used to interpret biomedical data were sufficient for the complexity of individualized medicine.

    Her central premise is that progress in personalized medicine may require not simply more data or larger computational models, but new mathematical ways of understanding biological systems.

    Rather than applying existing statistical approaches to biomedical problems, Mathematical Medicine explores whether ideas from pure mathematics can fundamentally change how biological questions are formulated, understood, and solved.

    The research is guided by the possibility that deeper mathematical understanding can reveal - and preserve- meaningful biological relationships even when data are limited, heterogeneous, or difficult to interpret using conventional approaches.

    This approach echoes a perspective expressed by the mathematician Mikhail Gromov: “This area does not yet exist. It will have to be invented.”

    It also reflects the empirical philosophy associated with the mathematician and quantitative investor Jim Simons: “We don't start with models. We start with data. We don't have any preconceived notions.” The aim is to allow biological observations to guide mathematical inquiry, rather than forcing them into existing computational frameworks.

    Sharada's research has contributed to investigations of complex and previously unexplained clinical conditions, including cases in which mathematical and multi-omic analyses helped identify potential diagnoses and therapeutic pathways. These investigations also motivate broader questions about how individual biological differences can inform our understanding of disease.

    The long-term vision is to establish Mathematical Medicine as a rigorous discipline connecting pure mathematics, molecular biology, and clinical medicine—advancing mathematics toward a foundation for understanding individual biology, preserving biological mechanisms and informing clinical decisions.

    Further information about Mathematical Medicine, its research vision, and opportunities for early philanthropic partnerships is available at:

    https://mathmed-2026.web.app/

  • Preston Kellenberger

    Preston Kellenberger

    Ph.D. Student in Biochemistry, admitted Autumn 2025

    BioI was raised in Saint Louis County, MO and completed my undergraduate degree in Biochemistry at The University of Missouri – Columbia. I’m most excited by translational problems that can be addressed through the structural understanding and engineering of biological molecules. At Stanford, I look forward to joining a collaborative community that spans broad scientific disciplines, and to contributing to research that advances human health. I love spending my extra time playing the drums, and I have served as a snare drummer for the world-class Madison Scouts and Cavaliers drum corps.

  • Chaitan Khosla

    Chaitan Khosla

    Wells H. Rauser and Harold M. Petiprin Professor and Professor of Chemistry and, by courtesy, of Biochemistry

    Current Research and Scholarly InterestsResearch in this laboratory focuses on problems where deep insights into enzymology and metabolism can be harnessed to improve human health.

    For the past two decades, we have studied and engineered enzymatic assembly lines called polyketide synthases that catalyze the biosynthesis of structurally complex and medicinally fascinating antibiotics in bacteria. An example of such an assembly line is found in the erythromycin biosynthetic pathway. Our current focus is on understanding the structure and mechanism of this polyketide synthase. At the same time, we are developing methods to decode the vast and growing number of orphan polyketide assembly lines in the sequence databases.

    For more than a decade, we have also investigated the pathogenesis of celiac disease, an autoimmune disorder of the small intestine, with the goal of discovering therapies and related management tools for this widespread but overlooked disease. Ongoing efforts focus on understanding the pivotal role of transglutaminase 2 in triggering the inflammatory response to dietary gluten in the celiac intestine.

  • Peter S. Kim

    Peter S. Kim

    Virginia and D. K. Ludwig Professor of Biochemistry

    Current Research and Scholarly InterestsOur research focuses on developing new strategies for vaccine creation. We also aim to generate vaccines targeting infectious agents that have eluded efforts to date. We integrate experimental approaches with protein language models to guide artificial evolution and enable efficient antibody and protein engineering. Our interdisciplinary approach aims to address critical global health challenges.